Holen Sie sich die Stockscreener-App
24.29
3.42%
-0.86
Handel nachbörslich:
24.34
0.05
+0.21%
Schlusskurs vom Vortag:
$25.15
Offen:
$25.08
24-Stunden-Volumen:
1.73M
Relative Volume:
1.26
Marktkapitalisierung:
$2.14B
Einnahmen:
$172.60M
Nettoeinkommen (Verlust:
$-285.42M
KGV:
-7.3689
EPS:
-3.2963
Netto-Cashflow:
$-323.17M
1W Leistung:
+8.05%
1M Leistung:
+10.06%
6M Leistung:
+48.11%
1J Leistung:
+115.91%
1-Tages-Spanne:
$24.20
$25.53
1-Wochen-Bereich:
$23.10
$25.53
52-Wochen-Spanne:
$8.58
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
24.29 | 2.22B | 172.60M | -285.42M | -323.17M | -3.2963 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
US Market Wrap: Is Syndax Pharmaceuticals Inc a defensive stock2026 Buyback Activity & Consistent Return Investment Signals - baoquankhu1.vn
SNDX Technical Analysis & Stock Price Forecast - Intellectia AI
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Should I Buy - Intellectia AI
Syndax Pharmaceuticals Inc (1T3.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Goldman Sachs Raises Price Target for SNDX to $34, Maintains 'Bu - gurufocus.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
Why (SNDX) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
SNDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Assenagon Asset Management S.A. - MarketBeat
MACD Signal: What makes Syndax Pharmaceuticals Inc stock attractive today2026 Recap & Consistent Profit Trade Alerts - baoquankhu1.vn
SNDX Analyst Rating Update: Mizuho Lowers Price Target | SNDX St - gurufocus.com
Mizuho Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $43 - Moomoo
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $43.00 by Analysts at Mizuho - MarketBeat
Hennion & Walsh Asset Management Inc. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Entry Recap: Is Syndax Pharmaceuticals Inc a good ESG investment2026 Price Momentum & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
SNDX: Jefferies Adjusts Syndax Pharmaceuticals Price Target to $40 | SNDX Stock News - gurufocus.com
Jefferies Financial Group Reiterates "Buy" Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
Mizuho lowers Syndax Pharmaceuticals stock price target on sales timing By Investing.com - Investing.com Canada
Syndax Pharmaceuticals Inc (1T3.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - gurufocus.com
Jefferies cuts Syndax Pharmaceuticals stock price target on valuation By Investing.com - Investing.com Canada
Vanguard (NYSE) reports 0 shares in Syndax after realignment (SNDX) - Stock Titan
Syndax (SNDX) Q4 2025 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template - ChartMill
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighWhat's Next? - MarketBeat
Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises - Investing.com Canada
Hedge Fund Bets: Is Syndax Pharmaceuticals Inc stock showing strong momentumMarket Trend Summary & Daily Price Action Insights - baoquankhu1.vn
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Hudson Bay Capital Management LP - MarketBeat
CEO Moves: Can Syndax Pharmaceuticals Inc stock double in the next yearMarket Activity Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish - AOL.com
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset - The Motley Fool
DAFNA Capital Reduces Syndax Pharmaceuticals Holding in Q4 2025News and Statistics - IndexBox
Kynam Capital Sells $8.18M in Syndax Shares, Position Value RisesNews and Statistics - IndexBox
Biotech Shares Surge 72% with $8 Million Transaction, Yet This Is Why a Fund Remains Optimistic - Bitget
Understanding Momentum Shifts in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals stock hits 52-week high at 25.16 USD By Investing.com - Investing.com Canada
Can Syndax Pharmaceuticals Inc scale operations efficiently2026 News Drivers & Fast Moving Stock Watchlists - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q4 2025 earnings preview - MSN
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? - Yahoo Finance
Kingdon Capital Management L.L.C. Purchases 400,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Granahan Investment Management LLC Has $6.10 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Cuts Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Syndax Pharmaceuticals Inc-Aktie (SNDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Goldan Keith A. | Chief Financial Officer |
Feb 09 '26 |
Sale |
21.03 |
3,410 |
71,705 |
140,429 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):